Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT04107168
Other study ID # MITRE
Secondary ID C7535/A27717
Status Recruiting
Phase
First received
Last updated
Start date July 8, 2020
Est. completion date July 8, 2025

Study information

Verified date February 2023
Source Cambridge University Hospitals NHS Foundation Trust
Contact MITRE Study Coordinator
Phone 01223 274746
Email cuh.mitre@nhs.net
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

This is a observational study to investigate how the microbiome correlates with efficacy and toxicity of immune checkpoint inhibitors in patients with advanced cancer.


Description:

The gastrointestinal microbiome of a healthy individual is comprised of many hundreds of bacteria species and thousands of bacteria strains. The composition of bacteria in an individual's microbiome can change over time and this can be influenced by factors including diet, drugs, genetics and infection. These bacteria play a central role in digestion of food, development and regulation of our immune system as well as our resistance to pathogens. Recent evidence suggest that a patient's intestinal microbiota composition plays a critical, though as yet poorly defined, role in determining both therapeutic efficacy and likelihood of significant adverse events to T-cell checkpoint inhibitor immunotherapy. Immune checkpoint inhibitors are revolutionising treatment of many types of metastatic cancer, including melanoma, renal and non-small cell lung cancer, in the expectation of improving patient overall survival. However, they have limitations as they do not work for all patients and can cause unpredictable, complex immune-related toxicities. The investigators will perform a detailed study of cancer patients receiving checkpoint inhibitors. Saliva and a series of stool samples will be collected from each patient to analyse their microbiome and will be linked to treatment response, by examining blood samples and - if available - tumour and organ samples. The investigators hope this work will enable personalisation of patient immunotherapies based on microbiome biomarkers, as well as precisely manipulate a patient's microbiota to optimise their immunotherapy. In addition, participants who have consented to take part in an optional sub-study may be offered a single nasopharyngeal swab for COVID-19 antigen before study entry. The investigators hope that that this identify correlations between the microbiome and COVID-19. Comparison with a limited cohort of healthy household members (up to 360 volunteers) acting as controls will provide additional essential information about the role of the patient-specific microbiome.


Recruitment information / eligibility

Status Recruiting
Enrollment 1800
Est. completion date July 8, 2025
Est. primary completion date July 8, 2024
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria for cancer patients: - Signed informed consent - Aged =18 years old - Histological or cytological confirmation of invasive malignancy - Due to commence palliative, adjuvant or neoadjuvant systemic therapy including an anti-PD-(L)1 antibody +/- anti-CTLA-4 antibody - Patients with unresectable disease must have radiologically and/or clinically measurable disease, by RECIST version 1.1; target lesions must not have been previously irradiated; baseline tumour assessments must be performed within 45 days prior to starting immune checkpoint inhibitor treatment - Received no prior immune checkpoint inhibitors (previous treatment with other types of anti-cancer therapy is determined by patient cohort; for patients with unresectable disease, prior adjuvant therapy with immune checkpoint inhibitor(s) is allowed). - Willing and able to comply with scheduled visits, treatment plans, sample collections and other study procedures Exclusion Criteria for cancer patients: - Other invasive malignancies diagnosed within the last year which are not fully resected, or in complete remission, or for which additional therapy is required - Significant acute or chronic medical or psychiatric condition, disease or laboratory abnormality which in the judgment of the investigator would place the patient at undue risk, or interfere with their ability to comply with the study. Examples may include, but are not limited to: - Patients with uncontrolled ischaemic heart or other cardiovascular event (e.g. myocardial infarction, new angina, stroke, transient ischaemic attack, or new congestive cardiac failure) within the last 6 months - Presence of active infection - Cirrhotic liver disease, known chronic active or acute hepatitis B, or hepatitis C - Current active, severe, or uncontrolled autoimmune condition, including but not limited to Crohn's disease and ulcerative colitis. - Women who are pregnant, plan to become pregnant or are lactating during the study period. - Requirement for non-physiological dose of oral steroids, or regular use of any other immunosuppressive agents; less than 10mg prednisolone or equivalent doses are allowed. Use of inhaled or topical steroids is allowed. Household control eligibility requirements: Confirmation of suitability to be a household control participant will be determined by completing a self-assessed questionnaire either at home or in clinic. Household controls must: - NOT have had any gastrointestinal infections i.e., parasites, viruses or diarrhoeal episodes during the last 6 months. - NOT have taken antibiotics for at least 6 months - NOT have or be recovering from any chronic intestinal disease such as: - Crohn's disease - Ulcerative colitis - Coeliac disease - Irritable bowel syndrome - Stomach ulcers - NOT have a chronic autoimmune disease or significant allergies e.g., multiple sclerosis, asthma requiring regular medication, psoriasis. - NOT have and NOT be recovering from any form of cancer. - NOT take proton pump inhibitors, steroids, other non-steroidal anti-inflammatory drugs such as ibuprofen or aspirin. - NOT had requirement to be hospitalised for treatment of COVID-19 In addition, household controls must sign informed consent and be aged =18 years old.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Nivolumab
A human immunoglobulin G4 (IgG4) monoclonal antibody, which binds to the programmed death-1 receptor (PD-1).
Pembrolizumab
A human immunoglobulin G4-kappa (IgG4-kappa) monoclonal antibody that targets PD-1.
Ipilimumab
A human immunoglobulin G1 (IgG1) monoclonal antibody raised against cytotoxic T lymphocyte antigen-4 (CTLA-4).
Durvalumab
A human immunoglobulin G1-kappa (IgG1-kappa) monoclonal antibody that binds to programmed death ligand 1 (PD-L1).
Tremelimumab
A fully human monoclonal antibody raised to target cytotoxic T lymphocyte-associated antigen 4 (CTLA-4).
Atezolizumab
A humanised IgG1 monoclonal antibody raised to target programmed death-ligand 1 (PD-L1).
Bevacizumab
A humanised IgG1 monoclonal antibody raised to target vascular endothelial growth factor (VEGF).

Locations

Country Name City State
United Kingdom Royal United Hospitals Bath NHS Foundation Trust Bath
United Kingdom University Hospitals Dorest NHS Foundation Trust Bournemouth
United Kingdom University Hospitals Bristol NHS Foundation Trust Bristol
United Kingdom Cambridge University Hospitals NHS Foundation Trust Cambridge
United Kingdom Velindre University NHS Trust Cardiff
United Kingdom Western General Hospital Edinburgh
United Kingdom The Queen Elizabeth Hospital King's Lynn NHS Foundation Trust King's Lynn
United Kingdom University Hospitals of Leicester NHS Foundation Trust Leicester
United Kingdom Norfolk and Norwich University Hospitals NHS Foundation Trust Norwich
United Kingdom Sheffield Teaching Hospitals NHS Foundation Trust Sheffield
United Kingdom University Hospital Southampton NHS Foundation Trust Southampton
United Kingdom Somerset NHS Foundation Trust Taunton
United Kingdom Royal Cornwall Hospitals NHS Trust Truro

Sponsors (2)

Lead Sponsor Collaborator
CCTU- Cancer Theme Microbiotica Ltd

Country where clinical trial is conducted

United Kingdom, 

Outcome

Type Measure Description Time frame Safety issue
Primary Can the microbiome signature predict progression-free survival (PFS) of 1 year or greater The primary outcome measure is the ability to predict for PFS of 1 year or greater for patients with advanced melanoma, renal and non-small cell lung cancer (cohorts 1-6). Minimum 1 year PFS
Secondary Can the microbiome signature predict PFS Measure the ability of the microbiome signature to predict 6 month PFS, 2 year PFS, overall response rate and median PFS in Cohorts 1-6. 1 year & 2 years PFS
Secondary Can the microbiome signature overall survival (OS) Measure the ability of the microbiome signature to median OS in Cohorts 1-6. Up to 6 years
Secondary Can the microbiome signature to predict relapse Measure the ability of the microbiome signature to predict for 1 or 2 year relapse after resection of high risk melanoma or renal cancer in cohorts 7-9. 1 year & 2 years relapse-free survival (RFS)
Secondary Does the microbiome correlate with treatment efficacy To compare pre-treatment oral and gut microbiome findings and their association with treatment efficacy. Up to 6 years
Secondary Correlate microbiome findings with incidence and characteristics of immune-related adverse events To correlate microbiome findings with incidence and characteristics of CTCAE V5-defined Grade 3 or greater immune-related adverse events in all enrolled cancer patients, and any association with response to immunosuppressants. Up to 6 years
Secondary Correlation microbiome findings and known characteristics of patients To correlate microbiome findings with aspects of pre-existing patient characteristics and behaviour including but not limited to diet, smoking history, BMI, use of antibiotics, steroids, proton pump inhibitors, non-steroidal anti-inflammatory drugs and probiotics. Up to 6 years
Secondary Control for the microbiome of cancer patients To compare the microbiome signature of cancer patients with a household control group of people who are not known to have cancer. Up to 6 years
Secondary Build a library of biological samples for future research To retain a library of biological samples (saliva, stool, blood and tumour as well as organ if available) with linked patient data for future research. Up to 6 years
See also
  Status Clinical Trial Phase
Completed NCT03918538 - A Series of Study in Testing Efficacy of Pulmonary Rehabilitation Interventions in Lung Cancer Survivors N/A
Recruiting NCT05078918 - Comprehensive Care Program for Their Return to Normal Life Among Lung Cancer Survivors N/A
Active, not recruiting NCT04548830 - Safety of Lung Cryobiopsy in People With Cancer Phase 2
Completed NCT04633850 - Implementation of Adjuvants in Intercostal Nerve Blockades for Thoracoscopic Surgery in Pulmonary Cancer Patients
Recruiting NCT06037954 - A Study of Mental Health Care in People With Cancer N/A
Recruiting NCT06006390 - CEA Targeting Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of CEA Positive Advanced Solid Tumors Phase 1/Phase 2
Recruiting NCT05583916 - Same Day Discharge for Video-Assisted Thoracoscopic Surgery (VATS) Lung Surgery N/A
Completed NCT00341939 - Retrospective Analysis of a Drug-Metabolizing Genotype in Cancer Patients and Correlation With Pharmacokinetic and Pharmacodynamics Data
Not yet recruiting NCT06376253 - A Phase I Study of [177Lu]Lu-EVS459 in Patients With Ovarian and Lung Cancers Phase 1
Recruiting NCT05898594 - Lung Cancer Screening in High-risk Black Women N/A
Active, not recruiting NCT05060432 - Study of EOS-448 With Standard of Care and/or Investigational Therapies in Participants With Advanced Solid Tumors Phase 1/Phase 2
Active, not recruiting NCT03575793 - A Phase I/II Study of Nivolumab, Ipilimumab and Plinabulin in Patients With Recurrent Small Cell Lung Cancer Phase 1/Phase 2
Active, not recruiting NCT03667716 - COM701 (an Inhibitor of PVRIG) in Subjects With Advanced Solid Tumors. Phase 1
Terminated NCT01624090 - Mithramycin for Lung, Esophagus, and Other Chest Cancers Phase 2
Terminated NCT03275688 - NanoSpectrometer Biomarker Discovery and Confirmation Study
Not yet recruiting NCT04931420 - Study Comparing Standard of Care Chemotherapy With/ Without Sequential Cytoreductive Surgery for Patients With Metastatic Foregut Cancer and Undetectable Circulating Tumor-Deoxyribose Nucleic Acid Levels Phase 2
Recruiting NCT06052449 - Assessing Social Determinants of Health to Increase Cancer Screening N/A
Recruiting NCT06010862 - Clinical Study of CEA-targeted CAR-T Therapy for CEA-positive Advanced/Metastatic Malignant Solid Tumors Phase 1
Not yet recruiting NCT06017271 - Predictive Value of Epicardial Adipose Tissue for Pulmonary Embolism and Death in Patients With Lung Cancer
Recruiting NCT05787522 - Efficacy and Safety of AI-assisted Radiotherapy Contouring Software for Thoracic Organs at Risk